Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis

Background and Objective: Myasthenia gravis (MG) is an autoimmune neuromuscular disease. Nearly 10–30% of patients with MG are refractory to conventional therapy. Rituximab (RTX), a monoclonal antibody targeting CD20, is increasingly used in autoimmune disorders. We performed a systematic review and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Cong Zhao, Meng Pu, Dawei Chen, Jin Shi, Zhuyi Li, Jun Guo, Guangyun Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-10-01
coleção:	Frontiers in Neurology
Assuntos:	myasthenia gravis refractory rituximab effectiveness meta-analysis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fneur.2021.736190/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!